Solid Q1 2025 Fuels Optimism for FY25
09/05/25 -"Novonesis delivered a strong start to FY25, with 11% organic revenue growth and a 310bps expansion in adjusted EBITDA margin to 38.3%, both ahead of consensus. All segments and regions contributed to ..."
Pages
60
Language
English
Published on
09/05/25
You may also be interested by these reports :
10/09/26
After an incredible 184% share price run from November 2023 to February 2026, UCB’s shares have lost c.28% of their value. This is largely because of ...
09/09/26
The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because ...
08/09/26
The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term ...
04/09/26
While we have tweaked our earnings estimates slightly higher, the decline in our target price is owing to the removal of a peer which was skewing the ...